Related Experiment Video
Updated: Sep 20, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Breast cancer--response rates to chemotherapeutic agents studied in vitro
Paul Kornblith1, Alan Wells, Michael J Gabrin
1Precision Therapeutics, Inc., 2516 Jane Street, Pittsburgh, PA 15203, USA. pkornblith@ptilabs.com
Background:
The biological efficacy of, and spectrum of action of, agents used in treatment of breast cancer are important issues in therapy planning.
Materials And Methods:
Techniques used involve monolayer culture and a quantitative microtiter plate-based chemo-response assay. Precision Therapeutics' overall assessability rate is 90% for tumors of all types. In this study, 148 specimens derived from breast cancer were studied. Of these, 111 were additionally studied histopathologically. Ninety-two percent of the 111 specimens were confirmed to be epithelioid in nature and, thus, compatible with cells of breast cancer origin.
Results:
In vitro chemo-response profiles indicated that individual agents stratified into groups, with cyclophosphamide and fluorouracil demonstrating responses of 69% and 57% respectively; doxorubicin, 45%; and docetaxel, paclitaxel and gemcitabine, 39, 27 and 36%, respectively.
Conclusion:
The spectrum of responsiveness of the individual agents was variable and not completely overlapping, as shown by the Venn diagrams.
